

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Cynata Therapeutics Limited
ABN	98 104 037 372

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Peter Gordon Webse
Date of last notice	2 June 2017

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	1. Direct 2. Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	2. Kay Joan Webse (spouse)
Date of change	11 November 2019
No. of securities held prior to change	1. 220,000 Ordinary Shares 2. 200,000 Unlisted Options – Exercise Price \$1.022, Expiry 17 November 2019
Class	Ordinary Shares and Unlisted Options – Exercise Price \$1.022, Expiry 17 November 2019
Number acquired	2. 120,775 Ordinary Shares
Number disposed	3. 200,000 Unlisted Options – Exercise Price \$1.022, Expiry 17 November 2019
Value/Consideration includes brokerage/gst <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$102,200 for the exercise of 100,000 Unlisted Options and nil consideration for the exercise of the remaining 100,000 Unlisted Options pursuant to cashless exercise facility.

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	1. 220,000 Ordinary Shares 2. 120,775 Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of 200,000 Unlisted Options – Exercise price \$1.022, 100,000 exercised for cash and 100,000 exercised pursuant to cashless exercise facility.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.